Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Bocanegra

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
International Journal of Molecular Sciences|March 29, 2023
mRNA Vaccines against SARS-CoV-2: Advantages and CaveatsMiriam Echaide, Luisa Chocarro de Erauso, Ana Bocanegra, et al.
EMBO Molecular Medicine|July 11, 2020
Systemic CD4 immunity: A powerful clinical biomarker for PD-L1/PD-1 immunotherapyMiren Zuazo, Hugo Arasanz, Ana Bocanegra, et al.
Frontiers in Immunology|December 17, 2020
Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy EfficacyMiren Zuazo, Hugo Arasanz, Ana Bocanegra, et al.
International Journal of Molecular Sciences|April 5, 2020
Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor TherapiesCarlos Hernandez, Hugo Arasanz, Luisa Chocarro, et al.
International Journal of Molecular Sciences|August 23, 2020
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade ImmunotherapyAna Bocanegra, Ester Blanco, Gonzalo Fernandez-Hinojal, et al.
International Journal of Molecular Sciences|February 11, 2023
Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid TumorsEster Blanco, Luisa Chocarro, Leticia Fernández-Rubio, et al.
International Journal of Molecular Sciences|November 11, 2022
Systemic CD4 Immunity and PD-L1/PD-1 Blockade ImmunotherapyDavid Escors, Ana Bocanegra, Luisa Chocarro, et al.
Gaceta Sanitaria|December 31, 2004
[Diagnostic agreement between emergency teams and hospital services]José M Fernández-Cotrina, Antonio J García-Ruiz, Mercedes Márquez-Castilla, et al.
Biomedicines|December 23, 2022
Cutting-Edge CAR Engineering: Beyond T CellsLuisa Chocarro, Ester Blanco, Leticia Fernández-Rubio, et al.
Cells|August 12, 2022
Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 InhibitorLuisa Chocarro, Ana Bocanegra, Ester Blanco, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
International Journal of Molecular Sciences|March 29, 2023
mRNA Vaccines against SARS-CoV-2: Advantages and CaveatsMiriam Echaide, Luisa Chocarro de Erauso, Ana Bocanegra, et al.
EMBO Molecular Medicine|July 11, 2020
Systemic CD4 immunity: A powerful clinical biomarker for PD-L1/PD-1 immunotherapyMiren Zuazo, Hugo Arasanz, Ana Bocanegra, et al.
Frontiers in Immunology|December 17, 2020
Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy EfficacyMiren Zuazo, Hugo Arasanz, Ana Bocanegra, et al.
International Journal of Molecular Sciences|April 5, 2020
Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor TherapiesCarlos Hernandez, Hugo Arasanz, Luisa Chocarro, et al.
International Journal of Molecular Sciences|August 23, 2020
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade ImmunotherapyAna Bocanegra, Ester Blanco, Gonzalo Fernandez-Hinojal, et al.
International Journal of Molecular Sciences|February 11, 2023
Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid TumorsEster Blanco, Luisa Chocarro, Leticia Fernández-Rubio, et al.
International Journal of Molecular Sciences|November 11, 2022
Systemic CD4 Immunity and PD-L1/PD-1 Blockade ImmunotherapyDavid Escors, Ana Bocanegra, Luisa Chocarro, et al.
Gaceta Sanitaria|December 31, 2004
[Diagnostic agreement between emergency teams and hospital services]José M Fernández-Cotrina, Antonio J García-Ruiz, Mercedes Márquez-Castilla, et al.
Biomedicines|December 23, 2022
Cutting-Edge CAR Engineering: Beyond T CellsLuisa Chocarro, Ester Blanco, Leticia Fernández-Rubio, et al.
Cells|August 12, 2022
Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 InhibitorLuisa Chocarro, Ana Bocanegra, Ester Blanco, et al.
Pageof 4